KarMac receives 2025 BWH Innovation Award

September 17, 2025

News

KarMac's pioneering approach to cellular therapy was recognized with a 2025 BWH Innovation Award. This honor highlights our ongoing commitment to developing novel, macrophage-directed immunotherapies for patients facing treatment-resistant breast cancer.

A first-in-class CAR-Monocyte immuno-oncology platform.

About Pipeline Founders News & Publications

Advisors Contact us

KarMac is a first-in-class CAR-Monocyte platform. We engineer immune cells to break down the biological shields around solid tumors, unlocking the immune system's full power to fight back.

KarMac receives 2025 BWH Innovation Award

More from the archive

Dr. Jennifer Guerriero named a Cancer Research Institute (CRI) Lloyd J. Old STAR

KarMac presents at 2026 ASGCT Annual Meeting

KarMac secures 2026 MGB GCTI Chemistry, Manufacturing & Controls (CMC) Award

KarMac awarded Poster of Distinction at 2026 MGB Celebration of Science

A first-in-class CAR-Monocyte immuno-oncology platform.